Siponimod could improve outcome in patients with SPMS

Novartis has announced today (23 March 2018) that results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) could reduce the risk of disability progression in patients. The results, which were published in The Lancet, revealed a significant reduction in the risk of 3- (primary endpoint) and 6-month confirmed disability progression with siponimod versus placebo. There is a high unmet need for new treatments that are safe and effective for patients with SPMS. If approved, siponimod would be the first disease-modifying therapy to delay disability progression in typical SPMS patients, including those...